Detail akcie GRAIL Rg-WI online

Business Summary: Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Grail Inc revenues increased 19% to $103.6M. Net loss decreased 84% to $309.2M. Revenues reflect Screening revenue increase of 25% to $96.2M. Lower net loss reflects Healthcare company segment loss decrease of 79% to $437.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$63.25 to -$8.74.